Biodesix, Inc. (NASDAQ:BDSX) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Biodesix, Inc. (NASDAQ:BDSX) have received an average rating of “Moderate Buy” from the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $32.50.

Several equities research analysts have issued reports on BDSX shares. William Blair upgraded shares of Biodesix from a “market perform” rating to an “outperform” rating in a research report on Friday, February 27th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $20.00 target price on shares of Biodesix in a research report on Tuesday, February 17th.

Biodesix Price Performance

Shares of BDSX opened at $10.64 on Friday. The company’s 50-day moving average is $14.57 and its 200-day moving average is $10.27. The firm has a market capitalization of $107.57 million, a PE ratio of -2.19 and a beta of 0.57. Biodesix has a fifty-two week low of $3.44 and a fifty-two week high of $20.21.

Biodesix (NASDAQ:BDSX) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.56. Biodesix had a negative net margin of 39.85% and a negative return on equity of 1,760.83%. The business had revenue of $28.76 million during the quarter, compared to the consensus estimate of $26.25 million. Analysts predict that Biodesix will post -3.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, Director Jack W. Schuler bought 20,000 shares of the company’s stock in a transaction dated Monday, January 26th. The stock was bought at an average price of $11.80 per share, with a total value of $236,000.00. Following the completion of the acquisition, the director owned 1,563,210 shares of the company’s stock, valued at $18,445,878. This represents a 1.30% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Scott Hutton sold 3,559 shares of the business’s stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $10.08, for a total transaction of $35,874.72. Following the completion of the sale, the chief executive officer directly owned 45,413 shares of the company’s stock, valued at approximately $457,763.04. The trade was a 7.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 9,052 shares of company stock worth $100,227. Insiders own 30.10% of the company’s stock.

Hedge Funds Weigh In On Biodesix

Hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC raised its stake in Biodesix by 5.6% in the 4th quarter. Geode Capital Management LLC now owns 42,453 shares of the company’s stock worth $289,000 after purchasing an additional 2,235 shares in the last quarter. State Street Corp grew its position in shares of Biodesix by 15.6% during the 4th quarter. State Street Corp now owns 17,802 shares of the company’s stock worth $121,000 after purchasing an additional 2,400 shares in the last quarter. Cetera Investment Advisers bought a new position in shares of Biodesix during the fourth quarter worth approximately $68,000. Thompson Davis & CO. Inc. bought a new position in shares of Biodesix during the first quarter worth approximately $170,000. Finally, Monashee Investment Management LLC raised its position in shares of Biodesix by 12.3% in the fourth quarter. Monashee Investment Management LLC now owns 112,344 shares of the company’s stock valued at $764,000 after buying an additional 12,348 shares in the last quarter. 20.96% of the stock is owned by institutional investors.

Biodesix Company Profile

Biodesix, Inc is a commercial-stage molecular diagnostics company headquartered in Boulder, Colorado, that develops and delivers blood-based tests to improve the diagnosis and management of lung diseases, including lung cancer. The company integrates advanced proteomic and, more recently, genomic technologies to offer noninvasive testing solutions designed to guide clinical decision-making. Biodesix operates a CLIA-certified and CAP-accredited laboratory, allowing it to process patient samples at scale and maintain rigorous quality standards.

The company’s flagship product, VeriStrat®, is a proteomic test that stratifies patients with non-small cell lung cancer into groups more likely to benefit from specific therapies.